BIOX
Bioceres Crop·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 3
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Significant Net Income Decline
Low Cash Short-term Debt Ratio
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BIOX
Bioceres Crop Solutions Corp.
A company that provides crop productivity solutions including seeds, biologicals, and fertilizers
Ocampo 210 bis, Predio CCT, Rosario, Province of Santa Fe, Argentina
--
Bioceres Crop Solutions Corp. is a Cayman Islands company established on November 14, 2017. The company is a leader in the development and commercialization of productivity solutions designed to regenerate agroecosystems while making crops more resilient to climate change. The company has a unique biotechnology platform with high-impact, licensed and patented technologies in seed and microbial agricultural inputs as well as biological and next-generation conventional crop nutrition and conservation solutions. In addition to the drought-tolerant seed technology HB4, the company has introduced digital solutions to support growers' decision-making and provide end-to-end traceability for production output.
Earnings Call
Q4/2025
Estimate EPS0.09
Actual EPS-0.7
Estimate Revenue110.08M
Actual Revenue74.70M
Bioceres Crop Solutions' Q4 2025 Earnings Call Contradictions: Cash Flow, Cost Savings, RinoTec, Syngenta, and Strategic Priorities Clash
Sep 09,2025 12:51
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.1
Actual EPS-0.02
Estimate Revenue61.87M
Actual Revenue60.60M
Bioceres' Q3 2025 Earnings Call: Contradictions in Argentina's Market Sentiment and U.S. Interest Rates
May 21,2025 12:15
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
BIOX has released its 2025 Q4 earnings. EPS was reported at -0.7, versus the expected 0.09, missing expectations. The chart below visualizes how BIOX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BIOX has released its 2025 Q4 earnings report, with revenue of 74.60M, reflecting a YoY change of -39.84%, and net profit of -48.00M, showing a YoY change of -4700.00%. The Sankey diagram below clearly presents BIOX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
